Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector

Journal of Gene Medicine

Volumn 8, Issue 10, 2006, Pages 1251-1261

  Sengupta, Amitava ^a   Banerjee, Debasish ^b   Chandra, Sarmila ^b   Banerjee, Subrata ^a  

^a SAHA INSTITUTE OF NUCLEAR PHYSICS   (India)

^b Park Clinic   (India)

Author keywords

BCR ABL; CML; EBV; p27Kip1; Rb; siRNA

Indexed keywords

BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; IMATINIB; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; THYMIDINE KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT; CONTROLLED STUDY; GENE TARGETING; HERPES SIMPLEX VIRUS; HERPESVIRUS VECTOR; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SUICIDE GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ACTIVE TRANSPORT, CELL NUCLEUS; APOPTOSIS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FUSION PROTEINS, BCR-ABL; G1 PHASE; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC ENGINEERING; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; MODELS, BIOLOGICAL; PHOSPHORYLATION; PIPERAZINES; POINT MUTATION; PYRIMIDINES; RETINOBLASTOMA; RNA INTERFERENCE; RNA, SMALL INTERFERING; S PHASE; TUMOR CELLS, CULTURED;

HUMAN HERPESVIRUS 4; SIMPLEXVIRUS;

EID: 33750494350     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.959     Document Type: Article

References (36)

1. bct/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-828.
2. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
3. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
4. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
5. Miyagishi M, Taira K. U6 promoter driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol 2002; 20: 497-500.
6. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2: 243-247.
7. Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 2003; 101: 1566-1569.
8. Wilda M, Fuchs U, Wossmann W, Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 2002; 21: 5716-5724.
9. Scherr M, Battmer K, Schultheis B, Ganser A, Eder M. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy. Gene Ther 2005; 12: 12-21.
10. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (ST1571) in chronic phase and blast crisis chronic myeloid leukemias. Cancer Cell 2002; 2: 117-125.
11. Kip1 expression. J Biol Chem 2001; 276: 23572-23580.
12. Kip1 through the phosphatidylinositol 3-kinase/AKT pathway. J Biol Chem 2000; 275: 39223-39230.
13. Dierov J, Dierova R, Carrol M. BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell 2004; 5: 275-285.
14. Jonuleit T, Kuip HVD, Miething C, et al. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood 2000; 1: 1933-1939.
15. Hara T, Kamura T, Nakayama K, Oshikawa K, Hatakeyama S, Nakayama KI. Degradation of p27(Kip1) at the G(O)-G(1l) transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem 2001; 276: 48937-48943.
16. Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 2005; 65: 3264-3272.
17. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8: 1153-1160.
18. Kip1 induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells. J Biol Chem 2005; 280: 18120-18129.
19. Shaffer DR, Viale A, Ishiwata R, et al. Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate. Proc Natl Acad Sci U S A 2005; 102: 210-215.
20. Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc Natl Acad Sci USA 2000; 97: 10538-10543.
21. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1 (+) leukemia cells. Nat Med 2004; 10: 1187-1189.
22. Rivas C, Miller ARM, Collado M, Lam EW-F, Apperley JF, Melo JV. BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir. Mol Ther 2001; 3: 642-652.
23. Basu U, Banerjee S. An engineered EBV vector expressing human factor VIII and von Willebrand factor in cultured B-cells. J Gene Med 2004; 6: 760-768.
24. Banerjee S, Livanos E, Vos JMH. Therapeutic gene delivery in human B lymphoblastoid-cells by engineered non-transforming, infectious Epstein-Barr virus. Nat Med 1995; 1: 1303-1308.
25. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr nuclear antigen-1. Nature 1995; 375: 685-688.
26. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 1996; 15: 3117-3126.
27. Saeki Y, Wataya-Kaneda M, Tanaka K, Kaneda Y. Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ liposomes. Gene Ther 1998; 5: 1031-1037.
28. Kamura T, Hara T, Matsumoto M, et al. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27,60 at G1 phase. Nat Cell Biol 2004; 6: 1229-1235.
29. Blai S, Scher HI, Cardo CC, Koff A. p27 as a target for cancer therapeutics. Cancer Cell 2003; 3: 111-115.
30. af1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003; 4: 425-429.
31. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002; 1: 117-123.
32. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
33. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
34. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1 -induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36: 453-461.
35. Luger SM, O'Brien SG, Ratajczak J, et al. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood 2002; 99: 1150-1158.
36. Chen J, Wall NR, Kocher K, et al. Stable expression of small interfering RNA sensitizes TEL-PDGFβR to inhibition with imatinib or rapamycin. J Clin Invest 2004; 113: 1784-1791.